Equity Profile
Pre-Earnings Brief
Neurocrine Biosciences (NBIX) is a biotechnology company focused on developing treatments for neurological and endocrine diseases. With a market cap of $13 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs through innovative therapies.
EPS
Earnings per share is a key indicator of profitability and performance, which investors closely monitor.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+31.75%
Avg Stock Reaction
+2.44%
In Q4 2025, Neurocrine reported an EPS of $1.88, beating estimates by 5.56%. However, the stock experienced a slight decline the following day.
Management Promises & Guidance
Analysts expect Neurocrine to report solid earnings, with a consensus EPS of $1.71 and revenue of $771 million. The company has a strong track record of beating earnings estimates.
Bull Case
If Neurocrine continues its trend of beating earnings expectations, it could see significant stock price appreciation, especially if revenue exceeds estimates.
Bear Case
Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could lead to a decline in stock price, especially given the high implied volatility.
EPS
$1.71Earnings per share is a key indicator of profitability and performance, which investors closely monitor.
Revenue
$771MRevenue figures provide insight into the company's sales performance and market demand for its products.
Expectations
The print will turn on these two things.
Q1
Will EPS exceed the consensus estimate of $1.71?
A beat on EPS would reinforce the company's strong performance trend and could boost investor confidence.
Q2
What is the revenue outlook for the next quarter?
Guidance on revenue will be crucial for assessing the company's growth trajectory and market demand for its products.
Edge
Why consensus could be wrong
The Street may underestimate Neurocrine's ability to leverage its product pipeline effectively, leading to stronger-than-expected revenue growth.
Supporting Evidence
Neurocrine has consistently beaten EPS estimates, indicating strong operational execution.
The options market is pricing in a larger move than historical averages, suggesting heightened expectations.
Recent product launches may drive unexpected revenue growth, which analysts have not fully accounted for.
Key Risk
If revenue exceeds $800 million, it could challenge the current bearish sentiment.
Edge
Pre-commit to what would confirm each case.
This quarter, the focus is on whether Neurocrine can maintain its strong earnings performance amid market expectations.
Bull Confirmed If
An EPS of $1.80 or higher would confirm the bull case, indicating strong operational performance.
Bear Confirmed If
An EPS below $1.50 would confirm the bear case, raising concerns about the company's growth prospects.
Pre-Earnings Positioning
Implied Move
±5.38%
Historical Avg
±2.9%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±5.4% while NBIX has averaged ±2.9% over the last 8 prints — setup is pricing rich.
30d HV
27.0%
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Neurocrine beats expectations, history suggests a potential stock increase of around 2.44%, confirming the company's growth narrative.
In-Line / Cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline in stock price, with historical patterns suggesting a potential drop of around 2.44%.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
LOEWS CORP